Thermo Fisher Scientific finalized its acquisition of Solventum's purification and filtration business for approximately $4.0 billion in cash, integrating it into the Life Sciences Solutions segment. The filtration and separation business is projected to generate around $750 million in 2025 revenue with mid- to high-single-digit organic growth. The original agreement, excluding Solventum's drinking water filtration business, was adjusted to lower the purchase price by $100 million. The deal reflects Thermo Fisher's expansion strategy in critical bioprocessing components, strengthening capabilities and market position in filtration solutions essential to biotech manufacturing.